Asymchem Laboratories (Tianjin) stock
002821.SZSHZAsymchem Laboratories (Tianjin) Co., Ltd., HealthcareISIN CNE100002BZ6
64Score 64 out of 100, Neutral
Price and trend
74 / 100
Price history
+62% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 12% above it.
Since November 2024 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 55).
The price is 22% below its 52-week high. Largest decline in 10 years: 84% (November 2021 to August 2024).
Chart figures for advanced users
- SMA 50$24.44
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$20.41
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)55
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.42
- The lowest closing price of the last twelve months.
- Resistance$29.36
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Asymchem Laboratories (Tianjin) Co., Ltd. belongs to the Biotechnology industry (China) and, with a market value of $8.29B, is number 45 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1B (up 14.9% year on year) and earnings of $169.84M (up 19.3%).
- For fiscal 2026, analysts expect on average revenue of $1.21B (up 21.2%) and adjusted earnings per share of $0.56 (up 40.4%).
Show more
- MEQIRI Score 64 out of 100 (Neutral): rank 215 of 702 in Healthcare, median 53.
- The P/E is 46.7 (Biotechnology median 45.8, own median of recent years 37.4).
- Our model puts fair value at $11.91, with the price 92% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $996.46M, financial debt $103.39M.Stability 81
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 59
Weaknesses
- Above fair valuePrice 92% above the fair value of $11.91.Valuation 34
- Negative free cash flowFree cash flow −$134.71M over the last 12 months.Fundamentals 59
- Volatile share priceVolatility 56% a year over the last 12 months.
Its standout strengths are stability and momentum, while capital allocation and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $8.50 and expensive above $19.84 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $1.34 (cash-flow model) and $22.47 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.6%. At 9.6% the fair value would be $11.81, at 7.6% it would be $12.03.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (45.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 18.1% on the twelve months before. Revenue has grown strongly since 2011, at around 22% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 42%, operating 19%, net 17%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 1 Apr 2027in 139 days
- Last reported
- 22 Oct 2026EPS reported $0.14
Analyst estimates
Earnings estimates have barely changed since 25 Oct 2026.
- Earnings per share
- $0.560.0%
- Revenue
- $1.21B+0.1%
- Earnings per share
- $0.75+0.1%
- Revenue
- $1.49B+0.7%
MEQIRI has stored the estimates since 25 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Asymchem Laboratories (Tianjin)
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 64
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Genscript Biotech1548.HK $9.09B48
- Praxis Precision MedicinesPRAX $9.08B42
- Krystal BiotechKRYS $9.06B66
- Protagonist TherapeuticsPTGX $8.77B68
- RemeGen688331.SS $8.26B44
- ALK-AbellóALK-B.CO $8.18B74
- AbivaxABVX.PA $8B35
- CytokineticsCYTK $7.82B33
ETFs that hold Asymchem Laboratories (Tianjin)
Held by 24 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers MSCI China A UCITS ETF 1CDBX9 | 0.12% | 0.35% | €107.81M |
| Xtrackers Harvest CSI A500 UCITS ETF 1DAH50 | 0.11% | 0.65% | €10.81M |
| WisdomTree Emerging Markets ex-State Owned Enterprises UCITS ETF AccumUSDXSOE | 0.03% | 0.32% | €17.98M |
Show 5 more
| Xtrackers MSCI China UCITS ETF 1CXCS6 | 0.02% | 0.65% | €1.51B |
| Franklin FTSE China UCITS ETFFLXC | 0.02% | 0.19% | €1.43B |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.01% | 0.17% | €5.24B |
| iShares Core MSCI EM IMI UCITS ETFIS3N | 0.00% | 0.18% | €37.98B |
| HSBC MSCI AC FAR EAST ex JAPAN UCITS ETF USDH411 | 0.00% | 0.45% | €400.6M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 13 Dec 2024)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.